Vyas V - Search Results

1

A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy.

Toppmeyer DL, Gounder M, Much J, Musanti R, Vyas V, Medina M, Orlando T, Pennick M, Lin Y, Shih W, Goodin S, Rubin E. Toppmeyer DL, et al. Among authors: vyas v. Med Sci Monit. 2003 Aug;9(8):PI99-104. Med Sci Monit. 2003. PMID: 12942041 Clinical Trial.

2

Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.

Licitra EJ, Vyas V, Nelson K, Musanti R, Beers S, Thomas C, Poplin E, Smith S, Lin Y, Schaaf LJ, Aisner J, Gounder M, Rajendra R, Saleem A, Toppmeyer D, Rubin EH. Licitra EJ, et al. Among authors: vyas v. Clin Cancer Res. 2003 May;9(5):1673-9. Clin Cancer Res. 2003. PMID: 12738720 Clinical Trial.

3

Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies.

DiPaola RS, Rafi MM, Vyas V, Toppmeyer D, Rubin E, Patel J, Goodin S, Medina M, Medina P, Zamek R, Zhang C, White E, Gupta E, Hait WN. DiPaola RS, et al. Among authors: vyas v. J Clin Oncol. 1999 Jul;17(7):2213-8. doi: 10.1200/JCO.1999.17.7.2213. J Clin Oncol. 1999. PMID: 10561278 Clinical Trial.

4

In vitro activation of irinotecan to SN-38 by human liver and intestine.

Ahmed F, Vyas V, Cornfield A, Goodin S, Ravikumar TS, Rubin EH, Gupta E. Ahmed F, et al. Among authors: vyas v. Anticancer Res. 1999 May-Jun;19(3A):2067-71. Anticancer Res. 1999. PMID: 10470149

5

Pharmacokinetics of orally administered camptothecins.

Gupta E, Vyas V, Ahmed F, Sinko P, Cook T, Rubin E. Gupta E, et al. Among authors: vyas v. Ann N Y Acad Sci. 2000;922:195-204. doi: 10.1111/j.1749-6632.2000.tb07038.x. Ann N Y Acad Sci. 2000. PMID: 11193895

6

High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin.

Ahmed F, Vyas V, Saleem A, Li XG, Zamek R, Cornfield A, Haluska P, Ibrahim N, Rubin EH, Gupta E. Ahmed F, et al. Among authors: vyas v. J Chromatogr B Biomed Sci Appl. 1998 Apr 10;707(1-2):227-33. doi: 10.1016/s0378-4347(97)00615-4. J Chromatogr B Biomed Sci Appl. 1998. PMID: 9613954 Clinical Trial.

7

The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s).

Gupta E, Luo F, Lallo A, Ramanathan S, Vyas V, Rubin E, Sinko P. Gupta E, et al. Among authors: vyas v. Anticancer Res. 2000 Mar-Apr;20(2A):1013-6. Anticancer Res. 2000. PMID: 10810389

8

Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).

Lalloo AK, Luo FR, Guo A, Paranjpe PV, Lee SH, Vyas V, Rubin E, Sinko PJ. Lalloo AK, et al. Among authors: vyas v. BMC Med. 2004 May 4;2:16. doi: 10.1186/1741-7015-2-16. BMC Med. 2004. PMID: 15125776 Free PMC article.

9

Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer.

Parmer TG, Ward MD, Yurkow EJ, Vyas VH, Kearney TJ, Hait WN. Parmer TG, et al. Among authors: vyas vh. Br J Cancer. 1999 Jan;79(1):59-64. doi: 10.1038/sj.bjc.6690012. Br J Cancer. 1999. PMID: 10408694 Free PMC article.

10

Mind-body therapy in the management and prevention of coronary disease.

Pandya DP, Vyas VH, Vyas SH. Pandya DP, et al. Among authors: vyas sh, vyas vh. Compr Ther. 1999 May;25(5):283-93. doi: 10.1007/BF02944271. Compr Ther. 1999. PMID: 10390658 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

329 results

Search Page

Filters